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This study aimed to systematically review neuropsychiatric lupus erythematosus (NPSLE) and establish a
simplified diagnostic criterion for NPSLE.
Publications from 1994 to 2018 in the database (Wanfang data (http://www.wanfangdata.com.cn/index.html)
and China National Knowledge Internet (http://www.cnki.net)) were included. In total, 284 original case reports
and 24 unpublished cases were collected, and clinical parameters were analyzed. An attempt was made to
develop a set of simplified diagnostic criteria for NPSLE based on cases described in the survey and literature;
moreover, and pathophysiology and management guidelines were studied.
The incidence rate of NPSLE was estimated to be 12.4% of SLE patients in China. A total of 408 NPSLE patients
had 652 NP events, of which 91.2% affected the central nervous system and 8.8% affected the peripheral
nervous system. Five signs (manifestations, disease activity, antibodies, thrombosis, and skin lesions) showed that
negative and positive predictive values were more than 70%, included in the diagnostic criteria. The specificity,
accuracy, and positive predictive value (PPV) of the revised diagnostic criteria were significantly higher than
those of the American College of Rheumatology (ACR) criteria (w2=13.642, 15.591, 65.010, po0.001). The area
under the curve (AUC) for revised diagnostic criteria was 0.962 (standard error=0.015, 95% confidence intervals
[CI] =0.933–0.990), while the AUC for the ACR criteria was 0.900 (standard error=0.024, 95% CI=0.853–0.946). The
AUC for the revised diagnostic criteria was different from that for the ACR criteria (Z=2.19, po0.05).
Understanding the pathophysiologic mechanisms leading to NPSLE is essential for the evaluation and design of
effective interventions. The set of diagnostic criteria proposed here represents a simplified, reliable, and cost-
effective approach used to diagnose NPSLE. The revised diagnostic criteria may improve the accuracy rate for
diagnosing NPSLE compared to the ACR criteria.
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’ INTRODUCTION
Systemic lupus erythematosus (SLE) affects the nervous
system, causing a variety of manifestations, including those
of the central nervous system (CNS) and peripheral nervous
system (PNS). The neuropsychiatric lupus erythematosus
(NPSLE) is a severe complication of SLE. NPSLE is chara-
cterized by a variety of neurological manifestations; its diag-
nosis has been a formidable challenge for rheumatologists (1).
NPSLE can present with numerous symptoms that are fre-
quently overlooked despite being associated with increased
mortality and morbidity (2). Because of the clinical hete-
rogeneity of NPSLE, and because we lack evidence-based
treatment and etiological insight, clinical management is
complex. Obviously, NPSLE does not occur due to a single
pathophysiological mechanism, and mechanisms may vary
according to the pathoanatomic localization of NPSLE—CNS,
PNS, and vascular.
The American College of Rheumatology (ACR) has iden-
tified 19 neuropsychiatric syndromes in SLE (3), which can
be divided into CNS and PNS manifestations. Although this
classification includes manifestations without clear physio-
logical and pathological mechanisms, it helps rheumatolo-
gists identify neurological involvement. The incidence of
NPSLE was also thought to have decreased as a result of the
improved outpatient detection and treatment of SLE. There
was no epidemiological data on NPSLE in China. Moreover,
to the best of our knowledge, no revised diagnostic criteria
have been reported. This review outlines our clinical studies
on NPSLE for approximately 20 years, based on the evidence
from literature reviews and surveys, recommendations for
the diagnostic criteria and management of NPSLE were estab-
lished. It is hoped that this effort will be useful to rheumato-
logists for the diagnosis and treatment of patients with NPSLE.
Definition of NPSLE
NPSLE (4) is a group of neurologic syndromes of the CNS
and PNS and/or of psychiatric syndromes observed in
patients with SLE in which other causes are excluded byDOI: 10.6061/clinics/2020/e1515
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laboratory, clinical, neuropsychological, and neuroimaging
tests (5). NPSLE is a general term used to describe the wide
range of SLE-related complications in the CNS and PNS. This
syndrome is different from other aspects of SLE because it
can occur without any serological changes. Focal disease in
the form of focal seizures or stroke is caused by lupus-related
coagulopathies (6). However, diffuse disease varies consider-
ably among patients; symptoms include memory impair-
ment, anxiety, general cognitive decline, and depression (7).
NPSLE can exhibit manifestations similar to those of hormo-
nal disturbances, metabolic, posterior reversible encephalo-
pathy syndrome, thrombotic thrombocytopenic purpura (TTP),
side effects of medications (especially corticosteroids), and
infectious.
Epidemiology of NPSLE
The reported prevalence of NPSLE ranges from 6% to 91%;
this variation is partly due to differences in research methods,
such as screening methods, follow-up duration, design types,
lack of specificity of many NP manifestations, and hetero-
geneous procedures of assessments (8,9). A specific study on
the prevalence of NPSLE has not yet been performed in China.
Thus, the author attempted to investigate NPSLE nationwide.
Publications from 1994 to 2018 in the database (Wanfang data
(http://www.wanfangdata.com.cn/index.html) and China
National Knowledge Internet (http://www.cnki.net)) were
included, using the terms ‘‘neuropsychiatric lupus erythema-
tosus’’, ‘‘neuropsychiatric lupus’’, ‘‘systemic lupus erythema-
tosus AND nervous system’’, ‘‘systemic lupus erythematosus
AND neuropsychiatric’’, the exclusion criteria were incom-
plete clinical data and unclear diagnosis. In total, 284 original
case reports and 24 unpublished cases were collected, and the
clinical parameters were analyzed. The incidence rate of
NPSLE was estimated to be 12.4% of SLE patients in China,
accounting for 10.2% of hospitalized patients with SLE. The
number of patients with NPSLE managed by rheumatism
departments has gradually increased in the last seven years
(2011–2018), but has decreased in emergency units and neu-
rology departments. This may be partly due to increased
awareness of NPSLE because research activities have often
been presented at meetings. Patients with a history of or
concurrent NPSLE, APL antibodies, skin lesions, as well as
those with generalized disease activity are at a higher risk of
developing NPSLE. The most common causes of death were
multiple organ failure (MOF, 35.2%), infection (22.3%), and
acute kidney injury (AKI, 17.5%) (Figure 1). Multiple logistic
regression indicated that pneumonia (OR=3.831; p=0.015),
AKI (OR=3.300; p=0.028), and cardiac complications (OR=3.256;
p=0.030) were significantly associated with mortality. Our study
demonstrated that the mean age of patients with NPSLE was
32.1±12.1 years (range 12-53 years), which was not signifi-
cantly different from the age of patients with SLE. However,
there was significant difference in mortality between age at
onset of NPSLE 414 and o14 years.
Pathophysiology of NPSLE
The pathogenic etiologies of NPSLE are likely to be
multifactorial and several pathophysiological mechanisms
have been implicated. NPSLE symptoms develop from
injury to the vasculature, blood-brain barrier (BBB), and
brain parenchyma. Studies have shown that cytokines and
autoantibodies may mediate the damage, leading to focal or
diffuse effects on the CNS. The PNS is not protected by a
BBB, so it is susceptible to the effects of immune complexes,
circulating autoantibodies, and other inflammatory mole-
cules (10).
The brain parenchyma may be the target of infiltrating
cells, cytokines, and autoantibodies, leading to either focal or
diffuse injury. Cytokines and chemokines enter into the CNS
through a permeabilized BBB from the peripheral circulation,
or be produced within the CNS by microglia and astrocytes.
Cytokines have direct effects on neurons and endothe-
lial cells, leading to apoptosis and dysfunction. In mice, pro-
inflammatory cytokines are associated with anhedonia,
depression, lethargy, and social isolation, similar associations
exist in humans (11). The cerebrospinal fluid (CSF) examina-
tion of patients with NPSLE showed that there were many
proinflammatory cytokines, including a proliferation-indu-
cing ligand (APRIL), tumor necrosis factor (TNF), interleu-
kin-6 (IL-6), IL-1, B cell–activating factor (BAFF), and interferon
alpha (IFN-a). Although these molecules can trigger inflam-
matory responses, the pathophysiologic mechanism(s) still
needs to be further studied.
Several antibodies are likely to be involved in the patho-
genesis of NPSLE. Anti-neuronal antibodies were the first
autoantibodies studied and recognized for the potential patho-
physiological effects of NPSLE. APL antibodies are asso-
ciated with cognitive impairment and cerebrovascular disease
in patients with SLE. Various effects on coagulation proteins,
platelets, and endothelial cells, including up regulation of
tissue factor, are attributed to APL antibodies, which are not
only serological markers, but also potentially direct lead to
thrombosis and other NPSLE manifestations. Alpha-tubulin
is considered as a target autoantigen of SLE, especially in
patients with NPSLE with severe CNS manifestations. Stu-
dies have shown that antibodies to the N-methyl-D-aspartate
receptor (NMDAR) may play a pathophysiological role in
emotional and cognitive impairment of SLE. Anti-glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) antibodies
are considered as new marker impairing cognitive processes
and affecting emotional changes. These autoantibodies lead
to selective impairment of cognition and spatial memory,
possibly due to a substantial reduction in the spines of
hippocampal pyramidal cells and dendritic processes, or as a
result of microglia activation (12).
Figure 1 - Causes of death in Chinese patients with neuropsy-
chiatric lupus erythematosus.
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The BBB protects the brain parenchyma, and its disruption
causes potentially toxic cells and molecules access to the brain.
Insults such as lipopolysaccharide (LPS) and systemic infec-
tions release soluble molecules, including IL-1, IL-6, and TNF,
which activate brain endothelial cells, leading to up regulation
of cell adhesion molecules, in turn causing BBB disruption
(13). Complement activation is another factor impairing BBB
integrity (14). The autoantibody must enter into brain tissue
through a breach in the BBB, leading to clinical symptoms,
and the location of the breach depends on the influencing
factors. Vascular injury is very common in patients with SLE.
Vascular abnormalities caused by vasculopathy, atherosclero-
tic disease, and hypercoagulability are other mechanisms
leading to the pathogenesis of NPSLE. Microvascular damage
leading to ischemia may result in ischemic patchy multiple
sclerosis–like demyelination and cortical atrophy observed in
lupus brains. Hemorrhage, tissue infarction, or more limited
focal neuron damaged are caused by impaired blood flow.
Clinical Manifestations of NPSLE
In our study, 408 NPSLE patients had 652 NP events of
which 91.2% affected the CNS and 8.8% affected the PNS. Of
those with NP manifestations, 81.5% were diffuse and 18.5%
were focal manifestations. Most patients, 61.2% had one
neuropsychiatric event, while 38.7% of the patients had two
or more manifestations. In 22.8%, nervous system involve-
ment was the initial presentation of SLE, while 57.9% of
NPSLE occurred at the onset of the disease or within the first
five years after the onset of SLE.
Our study, using the ACR definitions, detected the presence
of 13 of the 19 syndromes; cognitive dysfunction occurred in
42.1%, headache in 31.2%, acute confusional disorder in 16.8%,
cerebrovascular disease in 12.3%, mood disorder in 10.8%,
seizures in 8.9%, anxiety in 6.7%, psychoses in 6.5%, movement
disorders in 2.3%, and PNS impairment in 8.8%. The most
common clinical manifestations were cognitive dysfunction,
followed by headache and acute confusional disorder. More
than 40% of SLE patients had subjective complaints of cognitive
impairment. Headaches are common in patients with NPSLE,
tension headaches and migraine account for the majority.
Ischemic strokes occurred in 78.4% of the observed cardiovas-
cular disease (CVD), and 54.6% of stroke patients were found
to have a recurrent stroke, leading to 58.7% morbidity and a
26.8% mortality rate. Our study has identified several risk
factors for stroke in patients with NPSLE, including hyperten-
sion, advanced age, cigarette smoking, previous TIA or stroke,
diabetes mellitus, dyslipidemia, cardiac valvular disease, APL
antibodies, and a systemic lupus erythematosus disease activity
Index (SLEDAI) score of 410. Peripheral nerve involvement
occurs in 8.8% of patients with SLE, symptoms can be subtle or
severe and overlooked by the rheumatologists. The most
common manifestation is distal sensory or motor neuropathy
(65.9%). A very important finding in our study that deserves
emphasis was that the occurrence of neuropsychiatric events in
these patients was associated with increased organ damage and
reduced quality of life. This finding reinforces the need for
further studies to assess the relationship between SLE-related
morbidity and mortality and NPSLE manifestations.
Diagnostic challenges
NPSLE often presents as a diagnostic challenge, hamper-
ing early diagnostic of NPSLE is the lack of diagnostic
criteria. After excluding secondary causes, NPSLE can be
diagnosed if patients’ NP signs and symptoms are confirmed
with abnormalities in the CSF analysis, EEG, neuropsycho-
logical examination, biopsy, and neuroimaging studies (15).
A careful and detailed physical examination and medical
history, including a complete mental status and neurologic
evaluation, and medication review, must be performed on
each patient. Although NPSLE may be the sole or initial
manifestation of SLE activity, our study shows that NPSLE
frequently occurs when SLE is serologically and clinically
active. In our study, higher SLEDAI score and APL antibody
positivity increased the risk of development of NPSLE. Once
NPSLE is suspected, certain antibodies may be useful for
diagnosis, including APL, anti-ribosomal-P, anti-neuronal
and anti-ganglioside antibodies (16,17). By combining sero-
logical and clinical analysis with imaging findings, we can
determine that the patient’s clinical manifestations are asso-
ciated with active NPSLE rather than other causes. In our
study, five signs (manifestations, disease activity, antibodies,
thrombosis, and skin lesions) showed negative and positive
predictive values were more than 70%, and consequently
were included in the diagnostic criteria (Table 1).
To facilitate the diagnostic to the neurologic manifestations
of suspected NPSLE origin and to assist the rheumatologist
diagnosis it correctly, we suggest a revised set of diagnostic
criteria. Our goal was to combine the current research pro-
gress with the need to simplify the diagnostic methods. As
there is no diagnostic test for NPSLE, the diagnostic is con-
firmed by use of clinical assessment, disease activity, anti-
bodies, thrombosis, and skin lesions. Therefore, an attempt
was made to develop the diagnostic criteria for NPSLE based
on cases described in the survey and literature. A confirmed
diagnosis of SLE is essential for all the author’s criteria for
NPSLE. The diagnostic criteria proposed here are based on
an evidence-based approach; however, this is merely one
attempt to simplify the diagnostic path of NPSLE (Table 2).
There may be a need to expand the diagnostic criteria for
NPSLE, which would be achieved only through further studies.
Table 1 - Sensitivity and specificity of the symptoms and signs of neuropsychiatric lupus erythematosus and analysis of their positive
and negative predictive values.
Symptoms and signs Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%)
Manifestationsa 96.4 37.1 70.6 86.5
Higher SLEDAI score 80.6 42.1 79.4 73.9
Antibody positiveb 84.0 53.1 71.1 71.8
Thrombosis 78.0 63.2 70.8 71.4
Skin lesions 60.0 96.3 94.2 70.7
a Altered cognitive and/or neuropsychiatric status manifestations or sensorimotor neuropathy.
bAntiphospholipid (APL), anti-ribosomal-P (ARP), anti-neuronal, anti-ganglioside (GMI) and anti-Ro antibody, one of the antibodies is positive.
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Since the publication of the ACR criteria, several research-
ers have used these criteria in their studies. The ACR criteria
(18) had a high sensitivity (91%) but a low specificity (46%).
Our result showed that the specificity, accuracy, and posi-
tive predictive value (PPV) of the revised diagnostic criteria
were significantly higher than those of the ACR criteria
(w2=13.642, 15.591, 65.010, po0.001) (Table 3). The receiver
operating characteristic curve (ROC) of the revised diagnos-
tic criteria and ACR criteria analysis were individually
plotted, and their area under the curve (AUC) were calcula-
ted (Figure 2). Result showed that the AUC for the revised
diagnostic criteria was 0.962 (standard error=0.015, 95%
confidence intervals [CI] =0.933–0.990). The AUC for the ACR
criteria was 0.900 (standard error =0.024, 95% CI=0.853–0.946).
The AUC for the revised diagnostic criteria was different
from that for the ACR criteria (Z=2.19, po0.05). The diagno-
stic criteria proposed here can comprise a simplified, reliable,
and cost-effective approach for diagnosing NPSLE. Our study
revealed that revised diagnostic criteria had significantly better
accuracy, specificity and PPV than the ACR criteria. Therefore,
the revised diagnostic criteria may improve accurate diagno-
sis of NPSLE compared to the ACR criteria, which is reflected
in the improved higher AUC, specificity, and accuracy in our
study.
Severity and prognosis of NPSLE
The prognosis of patients with major NPSLE manifesta-
tions is less optimistic (19). Coma, stroke, and status epilep-
ticus are poor prognostic signs; aggressive evaluation and
treatment are needed to prevent death or residual neurologic
damage. Taking the factors including age, NP manifestations,
hypertension, AKI, infection and treatments into considera-
tion, univariate analysis showed that ageo14 years at onset
of NPSLE (p=0.001), AKI (po0.001), infection (p=0.036),
intrathecal methotrexate (MTX) plus dexamethasone (DXM)
treatment (po0.001) were the correlative factors of mortality.
Multivariate logistic regression confirmed that infection
(odds ratios [OR]=2.606, p=0.001), AKI (OR=4.711, p=0.003),
and age o14 years at onset of NPSLE (OR=10.434, p=0.001)
were risk factors for mortality, while intrathecal MTX plus
DXM treatment (OR=0.12, p=0.006) was a protective factor.
Moreover, we found that the proportion of patients under
14 years old in the deaths was significantly higher than that
in the survivals (34.8% vs. 10.2%).
Our study indicated that the mortality for NPSLE was
11.2%, which is similar to 10.8% reported in patients with
NPSLE (20). In our study, the mortality of patients with
NPSLE is high, so early diagnosis and appropriate treatment
are needed to improve the prognosis of NPSLE. This study
sought to determine the severity of illness in patients with
NPSLE, or the perceived severity, based on two indexes: the
British Isles lupus assessment group (BILAG) and SLEDAI.
In our study, the means±SD for BILAG and SLEDAI
scores were 26.62±6.02 and 15.75±3.20, respectively. Patients
who died had significantly higher scores than those
who survived: died versus survived=27.25±5.34 versus
16.88±3.87 (p=0.001) for BILAG and 21.25±2.19 versus
18.13±2.53 (p=0.019) for SLEDAI, respectively.
Management and treatment challenges
The management of patients with NPSLE includes provi-
ding symptomatic treatment, correcting the aggravating
factors, and taking specific measures related to the disease
process. Clinicians should try to identify and correct the pos-
sible aggravating factors, including metabolic or blood pres-
sure abnormalities, and possible offending drugs. Therapy
should not be delayed until the test results are available.
Symptomatic treatment will be required according to the
nature of NPSLE, and it may be initiated before disease-
specific treatment. Patients’ manifestations such as headaches,
anxiety or an infrequent seizure, or dysphoria, paresthesias
may only need psychotropic medications, analgesics and
antiseizure medications or neuroleptic agents, psychological
Table 2 - Definition and diagnostic criteria for neuropsychiatric
lupus erythematosus.
Definition of NPSLE
NPSLE is a group of neurologic syndromes of the central and peripheral
nervous system and/or of psychiatric syndromes observed in patients
with SLE in which other causes are excluded by laboratory, clinical,
neuropsychological tests and neuroimaging.
Prerequisite for diagnosis:
All the author’s criteria for NPSLE require the diagnosis of SLE.
Symptoms and signs:
1. Altered cognitive and/or neuropsychiatric status manifestations or
sensorimotor neuropathy.
2. Higher SLEDAI score (410).
3. Antiphospholipid (APL), anti-ribosomal-P (ARP), anti-neuronal,
anti-ganglioside (GMI) and anti-Ro antibody, one of the antibodies is
positive.
4. Complicated with tissue infarction, hemorrhage, or more limited focal
neuron injury results from impaired blood low (thrombosis).
5. Skin lesions
Diagnosis
Grade of NPSLE combinations of features requirements for diagnosis
NPSLE1: SLE plus at least one altered cognitive and/or neuropsychiatric
status manifestations or sensorimotor neuropathy and one of the
following: higher SLEDAI, antibody positivity, thromboembolism, or
skin lesions.
NPSLE2: SLE and at least one altered cognitive and/or neuropsychiatric
status manifestations or sensorimotor neuropathy.
Exclusion and provisions
Secondary causes such as medication side effects (especially steroids),
thyroid disease, infections, metabolic disturbances, TTP, valvular heart
disease, depression, sleep apnea, and psychosocial- or functional-
related conditions need to be excluded.
NPSLE 1: ‘‘definite’’ NPSLE; NPSLE 2: ‘‘suspected’’ NPSLE. TTP: thrombotic
thrombocytopenic purpura.
Table 3 - Comparison of the diagnostic performance of the two diagnostic criteria.
Examination method Sensitivity (%) Specificity (%) Accuracy (%) Positive predictive value (%) Negative predictive value (%)
ACR criteria 87.7 44.4 68.6 66.7 74.1
Revised criteria 82.8 71.4 80.9 93.3 46.3
w2 2.151 13.642 15.591 65.010 16.248
p 0.142 o0.001 o0.001 o0.001 o0.001
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support, respectively, and closely observe the progress of the
nervous system (18).
The treatment of NPSLE is mainly empirical, because few
controlled clinical trials have been conducted. For patients
with NPSLE who have progressive or severe, nonthrombotic
or diffuse symptoms such as severe depression, acute con-
fusional state, coma, psychosis, and aseptic meningitis, immu-
nosuppressive therapy is beneficial in addition to symptomatic
treatment. Most rheumatologists recommend taking 1 mg/kg
prednisone daily in divided doses (21). Conversion of pre-
dnisone to DXM (once a day, 12 to 20 mg) is another alter-
native, which is more effective than other corticosteroids in
crossing the BBB. Continued failure to respond is an indi-
cation of plasmapheresis or cytotoxic medications or both,
especially for comatose patients. In patients who did not res-
pond to corticosteroid therapy, intravenous cyclophospha-
mide (CYC, 0.75 to 1.0 g/m2) given every 3 to 6 weeks has
been reported to be beneficial (22,23). Intrathecal MTX plus
DXM (10 mg each time, once a week for 3 weeks) has been
used successfully in our study, which has a rapid onset of
action, less side effects, can improve drug bioavailability and
avoid systemic toxicity, is an effective treatment for NPSLE
(Table 4).
Patients with NPSLE with thrombotic or focal manifesta-
tions need to be evaluated immediately and aggressively. If
vasculitis is suspected, high doses of corticosteroids similar
to patients with nonthrombotic, diffuse, or severe manifesta-
tions are used. Cytotoxic medications should be used as early
as possible. Clinical studies have shown that CYC is more
effective than other immunosuppressive agents. Plasmapher-
esis may be beneficial within the first week to allow time for
the CYC and corticosteroids to take effect (21). Whether long-
term antiplatelet therapy can prevent atheroma formation or
thrombosis in the damaged vessel is unclear, but it is often
used clinically (24).
Most strokes caused by thrombosis are associated with APL
antibodies, while others are caused by emboli from damaged
heart valves (25). These patients should be treated with anti-
platelet drugs, statins, hydroxychloroquine, and/or anticoagu-
lation therapy. Many experts recommend that warfarin be used
lifelong in patients with cerebral artery thrombosis, maintaining
the international standardized ratio (INR) of 3.0 to 3.5 (21). In
addition, any patient with a lupus anticoagulant and recurrent
strokes should undergo testing for chromogenic factor X levels
and periodic factor II; both these values should be maintained
at 15% to 20% of normal to ensure adequate anticoagulation.
Studies suggest that antimalarial agents (AMs) may prevent
CNS flares, protect against worsening of brain lesions protect
from seizures, but not from headaches (23,26,27). In addition,
AMs diminish the risk for thrombosis by reducing blood
viscosity, red blood cell sludging, and platelet aggregation; all
of these can lead to cerebrovascular diseases in the context of
APL antibodies (28).
Patients with moderate to high titers of APL antibodies,
cerebral infarctions, and seizures should be started on anti-
coagulation therapy once seizures are controlled, despite the
higher risk of falls and cerebral trauma. In steroid-unrespon-
sive NPSLE, uncontrolled trials showed that B cell depletion
Figure 2 - The receiver operating characteristic curve of (A) American College of Rheumatology diagnostic criteria (area under the
curve=0.900) and (B) revised diagnostic criteria (area under the curve=0.962).
Table 4 - Comparison of the intravenous cyclophosphamide and intrathecal methotrexate plus dexamethasone.
Treatment Number of patients Response duration (days) Effective rate (%) Incidence of adverse events (%)
CYC 72 5.2±1.03 72.2 17.3
MTX+DXM 84 2.3±0.95 90.5 6.0
w2 or t - 6.539 4.386 5.112
p - o0.001 0.036 0.024
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therapy with anti-CD20 (rituximab) was effective (29). High-
dose CYC therapy or hematopoietic stem cell transplantation
may be considered for patients with resistant and severe
NPSLE (21). Patients with chronic inflammatory demyeli-
nating polyneuropathy (CIDP) or Guillain-Barré syndrome
frequently undergo plasmapheresis or intravenous immu-
noglobulin as additional therapy. Patients with mononeuritis
multiplex due to vasculitis should also be treated with cyto-
toxic medications such as CYC. In severe cases such as tran-
sverse myelitis, early combination of glucocorticoid and CYC
can provide better outcomes than glucocorticoid alone (23).
Future Directions
With the further study of the mechanism of immune abnor-
malities associated with active SLE, new therapies are being
developed and new targets have been identified for the treat-
ment of active disease. However, no new potential agents are
on the horizon for NPSLE. Understanding the pathophy-
siologic mechanisms leading to NPSLE is essential for the
evaluation and design of effective interventions (30). Several
difficult clinical situations need to be further elucidated.
First, we currently lack comprehensive understanding of the
mechanisms involved in NPSLE. Second, diagnostic tools
and criteria for patients with NPSLE are limited because
there are no in vivo imaging biomarkers providing direct
evidence for BBB dysfunction (31). Third, randomized con-
trol trials (RCTs) to evaluate specific treatments for NPSLE
are limited, and treatment strategies are based on small
control trials and expert recommendations. There are few
studies on NPSLE treatment; running such studies is diffi-
cult, because each trial may require a large number of patients
and collaboration between centers from several countries.
Finally, in clinical settings, the diagnosis and treatment of
NPSLE requires the collaboration of neurologists and psy-
chologists. In the next 10 years, the combination of NPSLE
pathophysiological mechanisms, RCTs, and new techniques
and methods may be helpful for the individualized treatment
of patients with NPSLE. The clinical significance of symptom
combination patterns and each symptom needs to be further
studied.
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